On March 16, 2026 Nerviano Medical Sciences S.r.l. ("NMS"), a global oncology-focused biopharmaceutical company, reported the presentation of two Trial-in-Progress posters featuring Itareparib (NMS-03305293) at the ESMO (Free ESMO Whitepaper) Targeted Anticancer Therapies (TAT) Congress 2026, taking place March 16–18, 2026 in Paris, France.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentations highlight ongoing clinical studies of Itareparib, NMS’s non-trapping, PARP1-specificinhibitor, the only third-generation inhibitor in clinical development. Itareparib is highly brain- and tumor-penetrant, providing an advantage for widely metastatic disease. Itareparib is being studied in combination with established DNA-damaging therapies in two areas of high unmet medical need: recurrent non-BRCA-mutated ovarian cancer and relapsed extensivestage small cell lung cancer (ES-SCLC), including patients with brain metastases.
The posters are:
Poster 57TiP – Phase 1a/1b Study of NMS-03305293 (Itareparib), a Brain-Penetrant, Non-Trapping PARP1- Selective Inhibitor, in Combination with Topotecan in Recurrent HR-Proficient / Refractory Ovarian Cancer.
Poster 58TiP – Poster 58TiP – PARPA-293-004: Phase 1b Study of NMS-03305293 (Itareparib), a Brain-Penetrant, Non-Trapping PARP1-Selective Inhibitor, in Combination with Temozolomide in Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
Both studies are open and actively recruiting:
Non-BRCA-mutated ovarian cancer study: NCT06930755
ES-SCLC study: NCT06931626
"These studies reflect our strategy of advancing Itareparib in combination settings where conventional PARP1 approaches have historically been constrained," said Lisa Mahnke, MD PhD, Group CMO. "We believe the differentiated profile of Itareparib has the potential to broaden the use of PARP1 biology beyond traditional BRCA-mutated settings and into larger patient populations through rational combinations with DNA-damaging therapies."
Ovarian cancer and ES-SCLC remain aggressive malignancies with significant unmet need, particularly in relapsed or refractory settings where patients often face limited treatment options and poor outcomes. Through these studies, NMS is evaluating Itareparib for its potential to enhance the activity of widely used chemotherapeutic backbones while maintaining a combination-enabling tolerability profile.
Itareparib is currently being developed across multiple tumor settings, with near-term clinical readouts expected from its ongoing combination programs.
About Itareparib
Itareparib is a novel PARP1 inhibitor, designed to be used in combination, and distinguished by a non-trapping mechanism of action as shown preclinically with high potency, PARP1 selectivity and brain penetrance. Clinically (Geurts et al ENA 2023), the profile improves on poor bone marrow features of trapping PARP1 inhibitors (Yap et al AACR (Free AACR Whitepaper) 2024) and thus removes traditional barriers to combining a DNA damage repair inhibitor with a DNA damaging agent in non-BRCA-mutated tumors.
(Press release, Nerviano Medical Sciences, MAR 16, 2026, View Source [SID1234663570])